ArticleIranian biomedical journal2014
Producing gelatin nanoparticles as delivery system for bovine serum albumin.
Article in Iranian biomedical journal, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Encapsulation of Protein-Based Drug Carriers for Controlled Loading and Releasing Efficiency: A Review.The protein journal · 2026Review
- Design and Characterization of GelMA Nanogels (nanoGelMA) via Desolvation and Photopolymerization for Drug Delivery Applications.Pharmaceutics · 2026Article
- Cross-Linkable Protein Nanofiber Aerogels for the Removal of Cationic and Anionic Dyes.ACS materials Au · 2026Article
- Bacterial ghosts embedded in natural hydrogels as drug delivery vehicles for cancer treatment.RSC advances · 2026Article
- Article
- Review
- Current Trends in Gelatin-Based Drug Delivery Systems.Pharmaceutics · 2023Review
- Fabrication of Encapsulated Gemini Surfactants.Molecules (Basel, Switzerland) · 2022Article
- Comprehensive comparison of theranostic nanoparticles in breast cancer.American journal of clinical and experimental immunology · 2022Review
- A Survey of Preclinical Studies Evaluating Nanoparticle-Based Vaccines Against Non-Viral Sexually Transmitted Infections.Frontiers in pharmacology · 2021Review
- EffectiveRSC advances · 2020Article
- Polyester functional graphenic materials as a mechanically enhanced scaffold for tissue regeneration.RSC advances · 2020Article
- Ultrasound-Assisted Encapsulation of Sacha Inchi (Polymers · 2019Article
- Development and Pre-Clinical Evaluation of Recombinant Human Myelin Basic Protein Nano Therapeutic Vaccine in Experimental Autoimmune Encephalomyelitis Mice Animal Model.Scientific reports · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundProgress in the field of biology and biochemistry has led to the discovery of numerous bioactive peptides and proteins in the last few decades. Delivery of therapeutic proteins/peptides has received a considerable amount of attention in recent years.
methodsIn this study, a two-step desolvation method was used to produce biodegradable hydrophilic gelatin nanoparticles (GNP) as a delivery system of protein model (BSA). The size and shape of the nanoparticles were examined by dynamic light scattering and scanning electron microscopy.
resultsParticles with a mean diameter of 200-300 nm were produced and the percentage of entrapment efficiency was found to be 87.4. The optimum amount of theoretical BSA loading was obtained, the release of BSA was monitored in vitro, and the mechanism of release was studied. The BSA release profile showed a biphasic modulation characterized by an initial, relatively rapid release period, followed by a slower release phase.
conclusionResults show that the two-step desolvation is an appropriate method for preparing GNP as a delivery vehicle for BSA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.